Nemolizumab Update: Galderma’s IL-31 Blocker Receives Filing Acceptances for PN and AD in Four More Countries May 7, 2024
AD Pipeline Watch: Inmagene’s Anti-OX40 Monoclonal Antibody Performs Well in Phase 2a AD Trial May 6, 2024
There’s Something About Eblasakimab: Aslan, Zenyaku Partner to Investigate How it Differs From Other Biologics for AD May 2, 2024